Blog Posts

Icahn School of Medicine at Mount Sinai – Results from the “REVERSE-IT” trial

icahn-mssm.university-tour.com

Apr 9, 2025, 07:12

Icahn School of Medicine at Mount Sinai – Results from the “REVERSE-IT” trial

Icahn School of Medicine at Mount Sinai posted on LinkedIn:

“Results from the “REVERSE-IT” trial show that bentracimab, an investigational monoclonal antibody, can safely and effectively reverse potentially catastrophic bleeding complications linked to ticagrelor, a common drug used to treat patients with acute coronary syndromes, prior heart attack, stroke, and coronary artery disease. The results were presented at ACC25 by Study Chair, Deepak L. Bhatt.

“If approved by the Food and Drug Administration, bentracimab could be a new life-saving option for someone having life-threatening bleeding, such as a brain hemorrhage,” says Dr. Bhatt.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Blog Posts

OncoDaily

Blog Posts

Icahn School of Medicine at Mount Sinai – Results from the “REVERSE-IT” trial